Wen-Yun Yang

A Bayesian phase I/II trial design to optimizing dose–schedule regimen with competing risk outcomes

CR-EffTox is proposed, a Bayesian adaptive phase I/II trial design that jointly models time-to-event DLT and DP using cause-specific hazard functions and generally outperforms methods that ignore competing risks or information borrowing, substantially improving correct selection probability and enhancing patient safety...